The enzyme inhibitor market is expected to witness growth owing to the growth of pharmaceutical drug industry. The key driver of this industry is the global spending on medicines in coalition with the increasing demand of specialty drugs. The North American region is accounted for more than 40% market share mainly due to the presence of leading players in US pharmaceutical industry. The Asia Pacific region is projected to see highest growth rate by 2022, particularly China is expected to witness more than 15% CAGR in the forecasted period.
Get Details of Enzyme
Inhibitor Market at: https://www.millioninsights.com/industry-reports/enzyme-inhibitor-market
Few factors that are expected to
thrust the market of enzyme inhibitor are research & development spending
by pharmaceutical companies, increasing competition, and technological
advancement. Upcoming new technologies have led to the new product development,
which has assisted the market to expect high growth over the forecasted period.
Sedentary lifestyle, pandemic threats, and higher risk of disease are few other
driving factors that will fuel in the growth of the market by 2022. The key
restrain that may slightly decrease the revenue growth of the market is due to
the patent expiration. Last few years patent expiration has led the
pharmaceutical industry to bear revenue losses of more than USD 20 billion each
year, but from the strategic actions by pharmaceutical companies it is
projected to go down to less than one third.
Enzyme inhibitor is a molecule,
which particularly binds with an enzyme to slow down its activity. It is
primarily used to kill a pathogen, which produces harmful diseases to maintain
the metabolic imbalance. In Agricultural industry, it is mainly used as a
pesticide to attract and destroy any pest. There are many applications of
enzyme inhibitor such as chemotherapy, metabolic control, pesticides, and
natural poisons. These inhibitors alter the functioning of enzymes and thus altering
the gene expression. Few other important applications such as male erectile
dysfunction, survival of bacterial pathogens, blocking specific protein in the
pancreas, regulation of neurological functioning, and stopping toxins that
pollutes environment are expected to drive the market in the near future.
The market is segmented by
reversible and irreversible as per the inhibitors binding with the enzymes.
Reversible inhibitor binding with enzyme is created through non-covalent
bonding such as ionic bonds or hydrogen bonds. Non-reversible inhibitor binding
with enzyme is created through covalent bonding by reacting chemically with the
enzyme.
The market segmentation by
inhibitor type into proton pump inhibitors (PPI), phosphodiesterase type 5
(PDE5) inhibitors, protease inhibitors, neuraminidase inhibitors, aromatase
inhibitors, reverse transcriptase inhibitor, statins, kinase inhibitors, and
angiotensin-converting enzyme (ACE) inhibitors. These inhibitors have varied
application in the pharmaceutical industry on the basis of reaction with the
pathogens such as PPIs for reducing the long lasting production of gastric
acid, PDE5 to treat the erectile dysfunction, protease for the treatment of
HIV/AIDS, kinase to block the action of protein kinases, reverse transcriptase
to generate complementary DNA, neuraminidase to block the influenza virus,
statins for reducing the cholesterol production, and angiotensin for the
treatment of hypertension.
Get Sample Copy of
Enzyme Inhibitor Market at : https://www.millioninsights.com/industry-reports/enzyme-inhibitor-market/request-sample
The market can also be segmented
by region into North America, Latin America, Europe, Asia Pacific, and Middle
East. Globally, the North America has the highest market share due to the
presence of largest players who produces the enzyme inhibitor drugs.
Particularly the US has the top five largest pharmaceutical companies based on
the revenue share. In totality, it has more than 150 companies, which are
competing in the enzyme inhibitor market. Research & development spending
in the US is highest among other countries of North American region.
The European region has the
second highest market share of enzyme inhibitor drugs mainly due to the high
government expenditure towards pharmaceutical industries and companies
involvement in producing the drug. Particularly in the United Kingdom, there
are companies such as GlaxoSmithKline and AstraZeneca, which accounts for
maximum revenue market share of enzyme inhibitor drugs.
The Asia Pacific region is the
fastest growing market mainly due to the increasing awareness of inhibitor
drugs and increasing investment from foreign companies. Particularly the
countries such as India, China, Japan, Russia, and Singapore accounts for more
than half of the market share among other countries in the region. This is due
to the high economic development, higher investments, increasing awareness, and
high population. In the forecasted period, the Asia pacific region is expected
to account for maximum share globally in at least 4-5 inhibitor drugs.
The key players that compete in
the enzyme inhibitor market are Novartis, Pfizer, Roche, Sanofi, Merch &
Co., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Gilead Sciences,
Takeda, Bayer, Astellas, Daiichi Sankyo, Baxter and Novo Nordisk. Out of these
companies, Novartis and Pfizer accounts for highest revenue market share and
highest R&D spending.
No comments:
Post a Comment